Clinical Trial for the Treatment of Non-Small Cell Lung Canc
These other companies plans to conduct the Acclaim-1 clinical trial in approximately 10 U.S. sites with about 100 patients (9-18 patients in the Phase 1 component and 82 patients in the Phase 2 component). An interim analysis would be performed after 53 events (i.e., progression of disease or death).
These other companies received U.S. Food and Drug Administration (FDA) Fast Track Designation for its Acclaim-1 patient population in January of 2020. Check disclaimer on my profile.